Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04514484
Title	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	Advanced Solid Tumor prostate carcinoma hepatocellular carcinoma transitional cell carcinoma differentiated thyroid gland carcinoma lung small cell carcinoma renal cell carcinoma thyroid gland medullary carcinoma lung non-small cell carcinoma Kaposi's sarcoma ovarian cancer head and neck cancer triple-receptor negative breast cancer melanoma
Therapies	Cabozantinib + Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA